John Maraganore

Yaron Werber × John Maraganore × Sam Fazeli × Matt Gline

Lilly’s $3.8B atai Beckley acquisition, ahead of a pivotal readout, extends its prevention and DTC “tech company” strategy while hedging potential obesity pressure a decade out.Roivant’s imminent brepocitinib launch combines orphan-market economics with pricing expected closer to IVIG’s $225K than Vyvgart’s $870K, while Merck’s $3,800 enlicitide and tau ASO tolerability keep affordability and validation in focus.

John Maraganore × Yaron Werber × Ami Fadia × Allison DeAngelis × Drew Armstrong

Rick Pazdur’s CDER appointment may steady FDA leadership, but the vague “plausible mechanism pathway” and its apparent conflict with uniQure keep regulatory execution a key risk.Competitive M&A—Lundbeck’s $2.6B Avadel bid versus Alkermes’ $2.1B offer—and Cogent’s PEAK, with 16.5-month mPFS in second-line GIST, create catalysts, while Intellia’s clinical hold keeps gene-editing safety unresolved.

Paul Matteis × Sam Fazeli × John Maraganore × Graig Suvannaveijh

XBI rose 11.9% in a month versus 2% for the S&P as 22,000 payroll additions missed 75,000 consensus, reinforcing September rate-cut expectations.Sanofi fell 10% after positive amlitelimab Phase 3, highlighting Dupixent’s replacement challenge before its 2031 patent expiry.HARMONi-A and FLAURA2 lead the fall catalyst stack, while 90% screening failure clouds Lilly’s Alzheimer’s prevention commercial viability.